Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer
1019.2500 -16.75 (-1.62%)
NSE Sep 25, 2025 15:31 PM
Volume: 1.1M
 

1019.25
-1.62%
HDFC Securities
Cadila reported a strong 3QFY16. A 335bps of QoQ improvement in EBITDA margin was driven by (1) 7% QoQ growth in the US, led by a few one-offs and HCQS, (2) Flat staff cost and (3) Other operating income of Rs 866mn (up 122% YoY). Higher R&D; (9.7% of sales) was offset by flat other expenses.
Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended